Diagnosis of immunodeficiency: Clinical clues and diagnostic tests

Current Allergy and Asthma Reports

Volumn 2, Issue 5, 2002, Pages 349-355

  Paul, Mary E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Ataxia Telangiectasia; Chronic Granulomatous Disease; Ectodermal Dysplasia; Primary Immunodeficiency Disease; Severe Combine Immunodeficiency

Indexed keywords

HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL PROCEDURES; METHODOLOGY; REVIEW;

HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC TESTS;

EID: 0036719682     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-002-0066-2     Document Type: Article

References (41)

1. [No authors listed] Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol 1999, 118(Suppl):1–34.
2. Primary Immunodeficiency Diseases: a Molecular Genetic Approach. Edited by Ochs HD, Smith CIE, Puck JM. New York: Oxford University Press; 1999.
3. Schroeder HW, Zhu ZB, March RE, et al.: Susceptibilty locus of IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol Med 1998, 4:72–86.
4. Cunningham-Rundles C, Bodian C: Common variable immunodeficiency: clinical and immunologic features of 248 patients. Clin Immunol 1999, 92:34–48. This is the largest recent cohort description of individuals with common variable immunodeficiency disease (CVID). DOI: 10.1006/clim.1999.4725
5. Tsukada S, Saffran DC, Rawlings DJ, et al.: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72:279–290. DOI: 10.1016/0092-8674(93)90667-F
6. Vetric D, Verochovsky I, Sideras P, et al.: The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature 1993, 361:226–233. DOI: 10.1038/361226a0
7. Yel L, Minegishi Y, Coustan-Smith E, et al.: Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996, 335:1486–1493. DOI: 10.1056/NEJM199611143352003
8. Buckley RH: Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000, 343:1313–1324. This is a comprehensive recent review of lymphocyte defects. DOI: 10.1056/NEJM200011023431806
9. Minegishi Y, Coustan-Smith E, Wang YH, et al.: Mutations in the human lambda 5/14.1 gene result in B cell deficiency and agammaglobulinemia. N Engl J Med 1998, 187:71–77.
10. Minegishi Y, Coustan-Smith E, Rapalus L, et al.: Mutations in Igalpha (CD79a) result in a complete block in B cell development. J Clin Invest 1999, 104:1115–1121. DOI: 10.1172/JCI7696
11. Minegishi Y, Rohrer J, Coustan-Smith E, et al.: An essential role for BLNK in human B cell development. Science 1999, 286:1954–1957. DOI: 10.1126/science.286.5446.1954
12. Fischer A: Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet 2001, 357:1863–1869. This is a comprehensive review of molecular mechanisms of primary immunodeficiency disorders. DOI: 10.1016/S0140-6736(00)04959-X
13. Puel A, Ziegler SF, Buckley RH, et al.: Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998, 20:394–937. DOI: 10.1038/3877
14. Macchi P, Villa A, Gilliani S, et al.: Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65–68. DOI: 10.1038/377065a0
15. Russe SM, Tayebi N, Nakajima H, et al.: Mutation of Jak3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science 1995, 270:797–800. DOI: 10.1126/science.270.5237.797
16. Schwarz K, Gauss GH, Ludwig L, et al.: RAG mutations in human B cell negative SCID. Science 1996, 274:97–99. DOI: 10.1126/science.274.5284.97
17. Elder ME, Lin D, Clever J, et al.: Human severe combined immunodeficiency due to a defect in ZAP-70, a cell tyrosine kinase. Science 1994, 264:1596–1599. DOI: 10.1126/science.8202712
18. Arpaia E, Shahar M, Dadi H, et al.: Defective T cell receptor signaling and CD8+ thymic selection in humans lacking ZAP-70 kinase. Cell 1994, 76:947–958. DOI: 10.1016/0092-8674(94)90368-9
19. Steimle V, Durand B, Barras E, et al.: A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995, 9:1021–1032.
20. Villard J, Lisowaska-Grospierre B, Van den Elsen P, et al.: Mutation of a RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency. N Engl J Med 1997, 337:748–753. DOI: 10.1056/NEJM199709113371104
21. Masternak K, Barras E, Zufferey M, et al.: A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998, 20:273–277. DOI: 10.1038/3081
22. Buckley RH, Schiff S, Schiff RI, et al.: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999, 340:508–616. DOI: 10.1056/NEJM199902183400703
23. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:699–672. DOI: 10.1126/science.288.5466.669
24. Hacein-Bey-Abina S, LeDeist F, Carlier F, et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002, 346:1185–1193. This describes a sustained cure of SCID patients with gene therapy. DOI: 10.1056/NEJMoa012616
25. Vantrappen G, Devriendt K, Swillen A, et al.: Presenting symptoms and clinical features in 130 patients with velocardio-facial syndrome. The Leuven experience. Genet Couns 1999, 10:3–9.
26. McDonald-McGinn DM, Kirschner R, Goldmuntz E, et al.: The Philadelphia story: the 22q11.2 deletion: report on 250 patients. Genet Couns 1999, 10:11–24.
27. Ramesh N, Geha RS, Notarangelo LD: CD40 ligand and the hyper IgM syndrome. In Primary Immunodeficiency Diseases: a Molecular Genetic Approach. Edited by Ochs HD, Smith CIE, Puck JM. New York: Oxford University Press; 1999:233–249.
28. Allen RC, Armitage RJ, Conley ME, et al.: CD40 ligand gene defects responsible for X-linked hyper IgM syndrome. Science 1993, 259:990–993. DOI: 10.1126/science.7679801
29. Korthauer U, Graf D, Mages HW: Defective expression of T cell CD40 ligand causes X-linked immunodeficiency with hyper IgM. Nature 1993, 361:539–541. DOI: 10.1038/361539a0
30. Noelle RJ, Roy M, Shepherd DM, et al.: A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992, 89:6550–6554. DOI: 10.1073/pnas.89.14.6550
31. Ferrari S, Giliani S, Insalaco A, et al.: Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA 2001, 98:12614–12619. DOI: 10.1073/pnas.221456898
32. Minegishi Y, Lavoie A, Cunningham-Rundles C, et al.: Mutations in activation -induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol 2000, 97:203–210. DOI: 10.1006/clim.2000.4956
33. Revy P, Muto T, Levy Y, et al.: Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 2000, 102:565–575. DOI: 10.1016/S0092-8674(00)00079-9
34. Jain A, Ma CA, Lius A, et al.: Specific missense mutations in Nemo result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001, 2:223–228. This is a recent molecular description of the cause of hyper-IgM syndrome with lymphocytic ectodermal dysplasia. DOI: 10.1038/85277
35. Mansour N, Woffendin H, Mitton S, et al.: Incontinentia pigmenti in a surviving male is accompanied by hypohydrotic ectodermal dysplasia and recurrent infection. Am J Med Genet 2001, 99:172–177. This is a recent molecular description of the cause of hyper-IgM syndrome with lymphocytic ectodermal dysplasia. DOI: 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1155>3.0.CO;2-Y
36. Doffinger R, Smahi A, Bessia C, et al.: X-linked anhydrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappa B signaling. Nat Genet 2001, 27:277–285. This is a recent molecular description of the cause of hyper-IgM syndrome with lymphocytic ectodermal dysplasia. DOI: 10.1038/85837
37. Srahna M, Remacle JE, Annamalai K, et al.: NF-kappaB is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cells. Clin Exp Immunol 2001, 125:229–236. DOI: 10.1046/j.1365-2249.2001.01601.x
38. Derry JM, Ochs MS, Francke U: Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 78:635–644. DOI: 10.1016/0092-8674(94)90528-2
39. Savistsky K, Bar-Shira A, Gilad S, et al.: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995, 268:1749–1753. DOI: 10.1126/science.7792600
40. Bemiller LS, Roberts DH, Starko KM, Curnutte JT: Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol Dis 1995, 21:239–247. DOI: 10.1006/bcmd.1995.0028
41. Luhn K, Wild MK, Eckhardt M, et al.: The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet 2001, 2811:69–72. DOI: 10.1038/88289